文献速递癫痫

药物治疗下的癫痫发作周期

Seizure Cycles under Pharmacotherapy.
PubMed 文献 · Ann Neurol · 2024-02-20

本研究回顾性分析88例参与RNS System临床试验的药物难治性局灶性癫痫成人患者最长10年数据,评估添加抗癫痫发作药物(ASM)对发作间期癫痫样活动(IEA)多日周期及癫痫发作的影响。在56次(33.3%)可分析的ASM试验中,ASM引入后多日IEA周期强度平均下降50%至70%,相对癫痫发作率同期下降50%至70%,持续长达12个月;前3个月IEA周期强度下降≥50%者后续12个月维持发作应答(≥50%发作率下降,p<10^-7)或超级应答(≥90%,p<10^-8)的概率更高。

要点

  • ASM引入后多日IEA周期强度平均下降50%至70%,相对癫痫发作率同期下降50%至70%,持续长达12个月。
  • 前3个月IEA周期强度下降≥50%者后续12个月维持发作应答(p<10^-7)或超级应答(p<10^-8)的概率更高。
  • IEA波动可能反映药物难治性局灶性癫痫的疾病活动度,有潜力作为预测治疗应答的生物标志物。

核心结论

  • 在这一大队列中,添加ASM后多日IEA周期强度下降与长达12个月的癫痫控制相关,提示IEA波动反映药物难治性局灶性癫痫的疾病活动度,可能具有作为预测治疗应答生物标志物的临床效用。

研究设计与样本

  • 回顾性分析88例参与RNS System临床试验的成人药物难治性局灶性癫痫患者最长10年数据,RNS System为记录IEA计数的颅内装置。
  • 评估添加ASM试验后数月内自我报告的致残性癫痫发作率及多日IEA周期强度(4至40天周期性的谱功率)的变化。
  • 采用生存分析和受试者工作特征曲线评估IEA变化作为癫痫控制预测指标的价值。

主要发现

  • 在168次添加ASM试验中,56次(33.3%)适合分析。
  • ASM引入后多日IEA周期强度平均下降50%至70%,相对癫痫发作率同期下降50%至70%,持续长达12个月。
  • ASM试验前3个月内IEA周期强度下降≥50%者,后续12个月维持发作应答(≥50%发作率下降)的概率更高(p<10^-7)。
  • ASM试验前3个月内IEA周期强度下降≥50%者,后续12个月维持超级应答(≥90%发作率下降)的概率更高(p<10^-8)。

临床怎么用

  • 作者认为,IEA波动可能反映药物难治性局灶性癫痫的疾病活动度,并可能具有作为预测治疗应答生物标志物的临床效用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study was undertaken to determine the effects of antiseizure medications (ASMs) on multidien (multiday) cycles of interictal epileptiform activity (IEA) and seizures and evaluate their potential clinical significance. METHODS: We retrospectively analyzed up to 10 years of data from 88 of the 256 total adults with pharmacoresistant focal epilepsy who participated in the clinical trials of the RNS System, an intracranial device that keeps records of IEA counts. Following adjunctive ASM trials, we evaluated changes over months in (1) rates of self-reported disabling seizures and (2) multidien IEA cycle strength (spectral power for periodicity between 4 and 40 days). We used a survival analysis and the receiver operating characteristics to assess changes in IEA as a predictor of seizure control. RESULTS: Among 56 (33.3%) of the 168 adjunctive ASM trials suitable for analysis, ASM introduction was followed by an average 50 to 70% decrease in multidien IEA cycle strength and a concomitant 50 to 70% decrease in relative seizure rate for up to 12 months. Individuals with a ≥50% decrease in IEA cycle strength in the first 3 months of an ASM trial had a higher probability of remaining seizure responders (≥50% seizure rate reduction, p < 10-7) or super-responders (≥90%, p < 10-8) over the next 12 months. INTERPRETATION: In this large cohort, a decrease in multidien IEA cycle strength following initiation of an adjunctive ASM correlated with seizure control for up to 12 months, suggesting that fluctuations in IEA mirror "disease activity" in pharmacoresistant focal epilepsy and may have clinical utility as a biomarker to predict treatment response. ANN NEUROL 2024;95:743-753.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Friedrichs-Maeder C, Proix T, Tcheng TK, et al. Seizure Cycles under Pharmacotherapy. Ann Neurol. 2024. PMID: 38379195. doi:10.1002/ana.26878

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。